Tech Company Financing Transactions

Intercept Pharmaceuticals Funding Round

On 8/13/2012, Intercept Pharmaceuticals received $30 million in Series C funding from OrbiMed, Genextra S.p.A. and private investors.

Transaction Overview

Announced On
8/13/2012
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors

OrbiMed (Lead Investor) (Klaus Veitinger)

Genextra S.p.A.

OrbiMed (Jonathan Silverstein)

Proceeds Purpose
This financing allows us to continue advancing our lead compound OCA in POISE, our Phase 3 PBC trial, while pursuing other therapeutic indications of interest.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10 Hudson Yards 37th Floor
New York, NY 10001
USA
Phone
Undisclosed
Email Address
Overview
For 11 years, Intercept has researched and developed a novel nuclear receptor (FXR). Find out how this science applies to liver and metabolic conditions.
Profile
Intercept Pharmaceuticals LinkedIn Company Profile
Social Media
Intercept Pharmaceuticals Company Twitter Account
Company News
Intercept Pharmaceuticals News
Facebook
Intercept Pharmaceuticals on Facebook
YouTube
Intercept Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Pruzanski
  Mark Pruzanski LinkedIn Profile  Mark Pruzanski Twitter Account  Mark Pruzanski News  Mark Pruzanski on Facebook
Chief Financial Officer
Sandip Kapadia
  Sandip Kapadia LinkedIn Profile  Sandip Kapadia Twitter Account  Sandip Kapadia News  Sandip Kapadia on Facebook
Chief Operating Officer
Jerome Durso
  Jerome Durso LinkedIn Profile  Jerome Durso Twitter Account  Jerome Durso News  Jerome Durso on Facebook
President
Lisa Bright
  Lisa Bright LinkedIn Profile  Lisa Bright Twitter Account  Lisa Bright News  Lisa Bright on Facebook
VP - General Counsel
Ryan Sullivan
  Ryan Sullivan LinkedIn Profile  Ryan Sullivan Twitter Account  Ryan Sullivan News  Ryan Sullivan on Facebook
VP - Human Resources
David Ford
  David Ford LinkedIn Profile  David Ford Twitter Account  David Ford News  David Ford on Facebook
VP - R & D
Christian Weyer
  Christian Weyer LinkedIn Profile  Christian Weyer Twitter Account  Christian Weyer News  Christian Weyer on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/13/2012: SolFocus venture capital transaction
Next: 8/13/2012: BrightWhistle venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary